Author

Sherryl A. Baker

Observed names: Baker, Sherryl, Sherryl Baker

Institution: GlaxoSmithKline (United States)

Observed institutions: University of Southern California, Poznan University of Medical Sciences, Nathan Kline Institute for Psychiatric Research, Dalhousie University, Children's Hospital Los Angeles, Thomas Jefferson University, University of California, Los Angeles, Pfizer (United States), Izaak Walton Killam Health Centre, Antwerp University Hospital, GlaxoSmithKline (United States), Novartis (United States), Novartis (Italy), Global Vaccines (United States), Covance (United Kingdom), Jan Biziel University Hospital No. 2 in Bydgoszcz, Canadian Centre for Vaccinology, KU Leuven

OpenAlex ID: A5112071449

Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents

2001 · John T. Walkup, Michael J. Labellarte, et al. · New England Journal of Medicine · 586

PDF

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies

2007 · George R. Siber, Ih Chang, et al. · Vaccine · 365

Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine

2010 · Kristina A. Bryant, Stan L. Block, et al. · PEDIATRICS · 191

Prevalence of Incidental Paranasal Sinuses Opacification in Pediatric Patients

1987 · Michael J. Diament, Melvin O. Senac, et al. · Journal of Computer Assisted Tomography · 177

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

2010 · Dorothee M. Kieninger, Kathrin Kueper, et al. · Vaccine · 169

Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial

2016 · Shabir A Madhi, Clare L Cutland, et al. · The Lancet Infectious Diseases · 168

Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age

2010 · Matthew D. Snape, Chaam L. Klinger, et al. · The Pediatric Infectious Disease Journal · 124

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults

2007 · Daniel A. Scott, Steven F. Komjathy, et al. · Vaccine · 107

Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine

2016 · Gilbert G.G. Donders, Scott A. Halperin, et al. · Obstetrics and Gynecology · 98

Psychosocial, Behavioral, and Medical Outcomes in Children with Epilepsy: A Developmental Risk Factor Model Using Longitudinal Data

1994 · Wendy G. Mitchell, Lawrence M. Scheier, et al. · PEDIATRICS · 89

Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: The National Drug Abuse Treatment Clinical Trials Network

2006 · Lawrence S. Brown, Steven Allan Kritz, et al. · Journal of Substance Abuse Treatment · 71

Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children

2009 · Lucy Chai See Lum, Charissa Fay Borja-Tabora, et al. · Vaccine · 70

A Comparison of Tests of the Difference in the Proportion of Patients Who Are Cured

1992 · Richard Sposto, Harland N. Sather, et al. · Biometrics · 64

Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy

2017 · Shabir A Madhi, Anthonet Koen, et al. · Clinical Infectious Diseases · 59

PDF

A placebo‐controlled screening trial of olanzapine, valproate, and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence

2005 · Malcolm S. Reid, Paul Casadonte, et al. · Addiction · 53

Reaction Time, Impulsivity, and Attention in Hyperactive Children and Controls: A Video Game Technique

1990 · Wendy G. Mitchell, John M. Chavez, et al. · Journal of Child Neurology · 38

Phase 1 trial of 13‐valent pneumococcal conjugate vaccine in Japanese adults

2008 · Daniel Scott, Jon Ruckle, et al. · Pediatrics International · 37

Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study

2019 · Geert Leroux-Roels, Fien De Boever, et al. · Vaccine · 33

PDF

Immunogenicity of malondialdehyde-modified low density lipoproteins

1987 · Boas Gonen, Joseph J. Fallon, et al. · Atherosclerosis · 28

Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine

2019 · Antonio Gonzalez-Lopez, Jaap Oostendorp, et al. · Clinical Immunology · 27

PDF

Mode-specific impact of relaxation training for hypertensive men with type a behavior pattern

1994 · David A.F. Haaga, Gerald C. Davison, et al. · Behavior Therapy · 19

A Placebo Controlled, Double-Blind Study of Mecamylamine Treatment for Cocaine Dependence in Patients Enrolled in an Opiate Replacement Program

2006 · Malcolm S. Reid, Burt Angrist, et al. · Substance Abuse · 16

An open-label randomized clinical trial of prophylactic paracetamol coadministered with 7-valent pneumococcal conjugate vaccine and hexavalent diphtheria toxoid, tetanus toxoid, 3-component acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b vaccine

2013 · Markus A Rose, Christine Juergens, et al. · BMC Pediatrics · 15

PDF

A clinical trial examining the effect of increased total CRM197 carrier protein dose on the antibody response to Haemophilus influenzae type b CRM197 conjugate vaccine

2008 · Vytautas Usonis, Vytautas Bakasenas, et al. · Vaccine · 15

A placebo‐controlled screening trial of celecoxib for the treatment of cocaine dependence

2005 · Malcolm S. Reid, Burt Angrist, et al. · Addiction · 14

Works count: 40

Citation count: 2,681

H-index: 20

I10-index: 27